Graeme Clark Collection

Permanent URI for this collection

http://hdl.handle.net/11343/375

Filters

1991 - 1997 3
Reset filters

Settings
Statistics
Citations
Author: Patrick, James × End date: 1997 × Start date: 1990 × Subject: otolaryngology ×

Search Results

Now showing 1 - 3 of 3
  • Item
    Thumbnail Image
    Engineering
    Patrick, James F. ; Seligman, Peter M. ; Clark, Graeme M. (Singular Publishing, 1997)
    The last two decades have seen major advances in cochlear implants for profoundly deaf people. Implants are now used by severely to profoundly deaf adults and children in almost every phase of daily life. They have become an established treatment, and today's expectations for all aspects of the cochlear implant system are much greater than they were for the experimental devices of the early 1980s. Hardware designs have improved to meet clinical and research demands, technological developments have made the devices smaller and more reliable, and speech processing research has yielded a series of improvements in patient benefit.
  • Item
    Thumbnail Image
    Comparison of current speech coding strategies
    Whitford, L. A. ; Seligman, P. M. ; Blamey, Peter J. ; McDermott, H. J. ; Patrick, J. F. ( 1993)
    This paper reports on two studies carried out at the University of Melbourne jointly with Cochlear Pty Ltd. The studies demonstrated substantial speech perception improvements over the current Multipeak strategy in background noise.
  • Item
    Thumbnail Image
    The Nucleus 22-channel cochlear implant system
    Patrick, James F. ; Clark, Graeme M. ( 1991)
    Cochlear implants have become the treatment of choice for profoundly deaf adults and children who obtain little or no benefit from conventional amplification. Sounds are translated into small electric currents that stimulate the auditory nerves in the cochlea and generate hearing sensations. The Nucleus cochlear implant is the result of more than 20 yr of research and development, first at the University of Melbourne, Australia and later by Cochlear Proprietary Limited (Sydney, Australia) in collaboration with the University of Melbourne. Today, the cochlear Mini-22 implant system is approved by the United States Food and Drug Administration (FDA) for use in adults and children, and has been implanted in more than 3000 patients worldwide. Although this chapter describes the cochlear implant system and clinical issues related to its use in children, much of the material has been derived from experience with adults. Furthermore, the Nucleus system is not static. It is being continually improved both in performance and ease of use. The purpose of this chapter is to describe developments leading up to and including the present Nucleus cochlear implant system. Other chapters in this issue present results and procedures relating to pediatric applications of the device.